Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin

Journal of Invasive Cardiology

Volumn 18, Issue 2, 2006, Pages 45-48

  Zalc, Silvio ^a   Lemos, Pedro A ^a   Esteves, Antonio ^a   Ribeiro, Expedito E ^a   Horta, Pedro ^a   Nicolau, Jose C ^a   Ramires, Jose A F ^a   Cohen, Marc ^a   Martinez, Eulogio E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; CREATINE KINASE MB; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; COMPRESSION; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CORONARY STENT; FALSE ANEURYSM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS;

AGED; ANTICOAGULANTS; CORONARY DISEASE; DEVICE REMOVAL; EARLY AMBULATION; ENOXAPARIN; FACTOR XA; FEASIBILITY STUDIES; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; STENTS;

EID: 33645991543     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Braunwald E, Antman EM, Beasley JW, et al. American College of Cardiology/American Heart Association. Committee on the Management of Patients with Unstable Angina. J Am Coll Cardiol 2002;40:1366-1374.
2. Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary syndromes and percutaneous coronary intervention. JAMA 2003;289:331-342.
3. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
4. Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity of low molecular weight heparins (LMWH). Haemostasis 1994;24:105-117.
5. Weitz JI. Low-molecular-weight heparin. N Engl J Med 1997;332:1330-1335.
6. Collet JPh, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663.
7. Ferguson JJ, Califf RM, Antman EM, et al. for the SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
8. Borentain M, Montalescot G, Bouzamondo A, et al. Intravenous low-molecular-weight heparin versus unfractionated heparin in percutaneous coronary angioplasty: A meta-analysis. Eur Heart J 2003;24(Abstr, Suppl):541.
9. Rao AK, Pratt C, Berke A, et al. Thrombolysis in myocardial infarction (TIMI) trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
10. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1392-1395.
11. Dudek D, Zymek P, Bartus S, Dubiel JS. The assessment of safety of enoxaparin administration during percutaneous transluminal coronary angioplasty after ticlopidine pretreatment. Application of low molecular weight heparins in prevention of coronary micro-embolization. Przegl 2001;58:484-486.
12. Kereiakes DJ, Grines C, Fry E, et al. for the NICE 1 and NICE 4 Investigators. National Investigators Collaborating on Enoxaparin. J Invasive Cardiol 2001;13:272-278.
13. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:1943-1950.
14. Chen WH, Lau CP, Lau YK, et al. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol 2002;14:439-442.
15. Pena PS, Montalescot G, Hulot JS, et al. Intravenous enoxaparin in patients undergoing percutaneous coronary intervention. Circulation 2004 (Suppl);110:III-616.
16. Korovesis S, Karvouni E, Karabinos I, et al. Comparison of enoxaparin and unfractionated heparin in coronary angioplasty. Hellenic J Cardiol 2005;46:46-51.
17. Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002;39:1738-1744.
18. Bianchini P, Osima B, Parma B, et al. Structural studies "in vivo" and "in vitro" pharmacological activities of heparin fractions fragments prepared by chemical enzymic depolimerization. Thromb Res 1985;40:49-58.
19. Bianchini P, Osima B, Parma B, et al. Lack of correlation between "in vitro" and "in vivo" antithrombotic activity of heparin fractions related compounds: Heparin sulfate as an antithrombotic agent "in vivo". Thromb Res 1985;40:597-607.
20. Nader HB, Lopes CC, Rocha HAO, et al. Heparins and heparinoids: Occurrence, structure and mechanism of antithrombotic and hemorrhagic activities. Curr Pharm Design 2004;10:951-966.